Migraine is a chronic medical condition affecting an estimated 38 million people in the United States. Throbbing, often one-sided moderate-to-severe head pain, accompanied by light and sound sensitivity and nausea/vomiting are the most common symptoms. Some migraine sufferers experience dizziness, visual symptoms, numbness or weakness on one side of the body, slowed thinking or trouble speaking.
Migraine predominantly effects young and middle-aged woman (that is, during their prime work and child-rearing years), though it can strike men and children as well. When untreated, the World Health Organization lists migraine as among the top ten most disabling medical conditions.
Our migraine research program aims to find better acute and preventive treatments for adults and children who suffer from migraine. Our current and upcoming studies include:
- Biohaven/ BHV 3000. Located just down the road from us in New Haven, Connecticut, Biohaven is a small company with a (potentially) big product: a CGRP oral medicine for acute treatment of migraine. By now most migraine sufferers have heard of CGRP (the inflammatory molecule in the brain that triggers a migraine), since several CGRP-blocking shots have come to market. This is a CGRP-blocker in a pill form. You may qualify for this study (in which you’ll get either the CGRP-blocker or a placebo pill) if you have 2-14 migraines a month. Learn More
- Tian/TX360. For those who don’t like pills or shots, this study may be for you. The TX360 uses small catheter placed deep in the nose to instill a tiny spray of medicine onto the SPG, a pain nerve that sits between the nose and brain. This study is for those with Chronic Migraine (15 or more headache days per month). Learn More
- Electrocore/Gammacore. This study is not about a pharmaceutical, but rather a hand-held device (looks like an electric razor), placed on the side of the neck, adjacent to the windpipe, for 2-3 minutes. The device is called Gammacore Sapphire, and it stimulates the vagus nerve, which is an important nerve for pain processing in the brain. Gammacore is already approved and available for acute treatment of migraine and cluster headache. This study examines the device’s utility as a daily migraine preventive therapy. Subjects will receive either the real Gammacore stimulator or a non-active “dummy” device. Learn More
- Allergan/Atogepant. Another CGRP-blocking pill, this time for daily use as a migraine prevention agent. Like nearly all research studies, participants will receive either Atogepant or a sugar pill for the double-blind phase, after which everyone gets the real drug in the open-label phase.Learn More
All studies at NEICR are available at no cost, and there is compensation for time and travel. Participation is voluntary, and you may withdraw at any time. To find out more, fill out the form below or call us at 203-914-1903.